FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3149636610> ?p ?o ?g. }

• W3149636610 endingPage "49" @default.
• W3149636610 startingPage "42" @default.
• W3149636610 abstract "Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetaxel-cyclophosphamide (TC) chemotherapy for early-stage breast cancer (EBC). A pragmatic randomised trial compared the superiority of G-CSF to ciprofloxacin and a cost-utility analysis were conducted.EBC patients receiving TC chemotherapy were randomised to ciprofloxacin or G-CSF. The primary outcome was a composite of FN and non-FN treatment-related hospitalisation. Secondary outcomes included; rates of FN, non-FN treatment-related hospitalisation, chemotherapy dose reductions/delays/discontinuations. Primary analysis was performed with the intention to treat population. Cost-utility analyses were conducted from the Canadian public payer perspective.458 eligible patients were randomised: 228 to ciprofloxacin and 230 to G-CSF. For the primary endpoint there was non-statistically significant difference (Risk difference = -6.7%, 95%CI = -13.5%-0.1%, p = 0.061) between ciprofloxacin patients (46,20.2%) and G-CSF (31,13.5%). Patients receiving ciprofloxacin were more likely to experience FN (36/228, 15.8% vs 13/230, 5.7%) than patients receiving G-CSF (p < 0.001). Non-FN treatment-related hospitalisation occurred in 40/228 (17.5%) of ciprofloxacin patients vs 28/230 (12.2%) of G-CSF patients (p = 0.12). There were no differences in other secondary outcomes. G-CSF was associated with an incremental cost-effectiveness ratio of C$1,760,796 per one quality-adjusted life year gained.The primary endpoint of superiority of G-CSF over ciprofloxacin was not demonstrated. While there were reduced FN rates with G-CSF, there were no differences in chemotherapy dose delays/reductions or discontinuations. With the commonly used willingness to pay value of C$50,000/QALY, G-CSF use was not cost-effective compared to ciprofloxacin and deserves scrutiny from the payer perspective." @default.
• W3149636610 created "2021-04-13" @default.
• W3149636610 creator A5022700654 @default.
• W3149636610 creator A5026335419 @default.
• W3149636610 creator A5030689616 @default.
• W3149636610 creator A5032920417 @default.
• W3149636610 creator A5038614820 @default.
• W3149636610 creator A5043408743 @default.
• W3149636610 creator A5045101227 @default.
• W3149636610 creator A5047689900 @default.
• W3149636610 creator A5055242194 @default.
• W3149636610 creator A5055430046 @default.
• W3149636610 creator A5056756378 @default.
• W3149636610 creator A5060373660 @default.
• W3149636610 creator A5061586507 @default.
• W3149636610 creator A5063784491 @default.
• W3149636610 creator A5067756723 @default.
• W3149636610 creator A5068186947 @default.
• W3149636610 creator A5070650433 @default.
• W3149636610 creator A5078027320 @default.
• W3149636610 creator A5080505420 @default.
• W3149636610 creator A5082092633 @default.
• W3149636610 date "2021-08-01" @default.
• W3149636610 modified "2023-10-18" @default.
• W3149636610 title "A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia" @default.
• W3149636610 cites W1915661725 @default.
• W3149636610 cites W1965726256 @default.
• W3149636610 cites W2004682667 @default.
• W3149636610 cites W2044868127 @default.
• W3149636610 cites W2048921324 @default.
• W3149636610 cites W2077962461 @default.
• W3149636610 cites W2079785419 @default.
• W3149636610 cites W2110645520 @default.
• W3149636610 cites W2115432999 @default.
• W3149636610 cites W2117366141 @default.
• W3149636610 cites W2131058213 @default.
• W3149636610 cites W2151423894 @default.
• W3149636610 cites W2160137717 @default.
• W3149636610 cites W2169403306 @default.
• W3149636610 cites W2170199384 @default.
• W3149636610 cites W2533671240 @default.
• W3149636610 cites W2791921511 @default.
• W3149636610 cites W2794179848 @default.
• W3149636610 cites W2803790911 @default.
• W3149636610 cites W2885814352 @default.
• W3149636610 cites W2887724188 @default.
• W3149636610 cites W2919830364 @default.
• W3149636610 cites W2946432848 @default.
• W3149636610 cites W3016716571 @default.
• W3149636610 cites W3020277203 @default.
• W3149636610 cites W4231687826 @default.
• W3149636610 doi "https://doi.org/10.1016/j.breast.2021.03.012" @default.
• W3149636610 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8095051" @default.
• W3149636610 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33901921" @default.
• W3149636610 hasPublicationYear "2021" @default.
• W3149636610 type Work @default.
• W3149636610 sameAs 3149636610 @default.
• W3149636610 citedByCount "4" @default.
• W3149636610 countsByYear W31496366102021 @default.
• W3149636610 countsByYear W31496366102022 @default.
• W3149636610 countsByYear W31496366102023 @default.
• W3149636610 crossrefType "journal-article" @default.
• W3149636610 hasAuthorship W3149636610A5022700654 @default.
• W3149636610 hasAuthorship W3149636610A5026335419 @default.
• W3149636610 hasAuthorship W3149636610A5030689616 @default.
• W3149636610 hasAuthorship W3149636610A5032920417 @default.
• W3149636610 hasAuthorship W3149636610A5038614820 @default.
• W3149636610 hasAuthorship W3149636610A5043408743 @default.
• W3149636610 hasAuthorship W3149636610A5045101227 @default.
• W3149636610 hasAuthorship W3149636610A5047689900 @default.
• W3149636610 hasAuthorship W3149636610A5055242194 @default.
• W3149636610 hasAuthorship W3149636610A5055430046 @default.
• W3149636610 hasAuthorship W3149636610A5056756378 @default.
• W3149636610 hasAuthorship W3149636610A5060373660 @default.
• W3149636610 hasAuthorship W3149636610A5061586507 @default.
• W3149636610 hasAuthorship W3149636610A5063784491 @default.
• W3149636610 hasAuthorship W3149636610A5067756723 @default.
• W3149636610 hasAuthorship W3149636610A5068186947 @default.
• W3149636610 hasAuthorship W3149636610A5070650433 @default.
• W3149636610 hasAuthorship W3149636610A5078027320 @default.
• W3149636610 hasAuthorship W3149636610A5080505420 @default.
• W3149636610 hasAuthorship W3149636610A5082092633 @default.
• W3149636610 hasBestOaLocation W31496366101 @default.
• W3149636610 hasConcept C126322002 @default.
• W3149636610 hasConcept C168563851 @default.
• W3149636610 hasConcept C203092338 @default.
• W3149636610 hasConcept C2776694085 @default.
• W3149636610 hasConcept C2776755627 @default.
• W3149636610 hasConcept C2777063308 @default.
• W3149636610 hasConcept C2777767877 @default.
• W3149636610 hasConcept C2778512257 @default.
• W3149636610 hasConcept C2778850193 @default.
• W3149636610 hasConcept C2781190966 @default.
• W3149636610 hasConcept C501593827 @default.
• W3149636610 hasConcept C71924100 @default.
• W3149636610 hasConcept C86803240 @default.
• W3149636610 hasConcept C89423630 @default.
• W3149636610 hasConceptScore W3149636610C126322002 @default.

• next